)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
AstraZeneca
AstraZeneca (AZN) investor relations material
AstraZeneca Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary10 Feb, 2026
Executive summary
Total revenue for FY 2025 rose 8% at constant exchange rates to $58.7bn, with product revenue up 10%, driven by strong global demand and robust performance across all therapy areas and geographies, including 16 blockbuster medicines and 16 positive Phase III trial readouts.
Achieved core EPS of $9.16, up 11% year-over-year, and maintained low concentration risk through a diversified portfolio and geographic reach.
Over 100 Phase III trials are ongoing, with 20+ readouts expected in 2026 and a risk-adjusted peak revenue potential exceeding $10bn.
Ordinary shares began trading on the NYSE in February 2026, harmonizing listings across major exchanges.
Strategic investments in R&D, manufacturing, and next-generation innovation platforms, including weight management, ADCs, and cell and gene therapy.
Financial highlights
FY 2025 total revenue was $58.7bn (+8% CER); product revenue $58.6bn (+10% CER); core EPS $9.16 (+11% CER); reported EPS $6.60 (+43% CER).
Gross margin was 82%; core operating margin 31%; operating profit $13.7bn (+36% CER); EBITDA $19.5bn (+17%).
Q4 2025 total revenue was $15.5bn (+2% CER); core EPS $2.12.
Cash flow from operations grew 23% to $14.6bn; CapEx was $3.3bn, with a planned increase of about one-third in FY 2026.
Second interim dividend of $2.17 per share declared, bringing total FY 2025 dividend to $3.20, with a planned increase to $3.30 in FY 2026.
Outlook and guidance
FY 2026 total revenue expected to grow mid- to high-single digits at CER, with core EPS projected to rise by a low double-digit percentage.
Core tax rate anticipated between 18%-22%; FX impact expected to be low single-digit positive on revenue and neutral on core EPS.
CapEx to increase by one-third in 2026 to support expansion in the US, China, and Singapore.
R&D expenses to be at the upper end of low 20s% of revenue in 2026, reflecting investment in late-stage pipeline.
Dividend to increase to $3.30 per share in 2026.
Implications of Datroway TROPION-Lung12 discontinuation
Rationale for $15bn China investment
China legal proceedings impact
Key 2026/27 readouts for post-2030 growth
Weight management strategy in a crowded market
China market profitability vs. group, 2026 outlook
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next AstraZeneca earnings date
Q1 202629 Apr, 2026
AstraZeneca
Next AstraZeneca earnings date
Q1 202629 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Anglo-Swedish Pharmaceuticals
AstraZeneca is a multinational biopharmaceutical company established in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Headquartered in Cambridge, UK, the firm operates globally, specializing in the research, development, manufacturing, and commercialization of prescription medications. It focuses on a range of therapeutic areas including oncology, cardiovascular, renal, metabolism, and respiratory diseases. AstraZeneca's products cater to a diverse set of medical needs and are distributed in numerous countries worldwide. The company is a major player in the global pharmaceutical industry, maintaining a strong commitment to scientific research and the development of new medicines.
A Successful Merger
As previously mentioned, AstraZeneca came to be following the merger of two established pharmaceutical companies. Astra AB, with roots dating back to 1913, had a notable history in pharmaceutical production, introducing various medicines to the market over the decades. Zeneca on the other hand traces its roots back to 1993 after separating from Imperial Chemical Industries. The British half of the modern-day company had a footprint in both therapeutic products and agrochemicals, although it eventually divested from the latter. The merger of these two entities aimed to consolidate resources, streamline research and development processes, and enhance their presence in the global pharmaceutical market. The combined company, now known as AstraZeneca, has since played a significant role in the industry, building upon the foundational knowledge and experience of the two merged parties.
Research and Development
AstraZeneca primarily focuses on the discovery, development, and commercialization of prescription medicines. Their core areas of activity encompass a range of medical conditions, including respiratory, cardiovascular, renal, metabolic, oncology, and autoimmune diseases. The company also engages in significant research and development efforts, with research centers in the UK, Sweden, and the USA. This focus AstraZeneca was one of the pharmaceutical companies heavily involved with the global effort of finding a suitable vaccine during the Covid-19 pandemic. This is an effort they succeeded in, and together with companies like Pfizer and Moderna, they were a key player in the global vaccination effort.
Serving Patients Worldwide
As is common with large pharmaceutical companies, AstraZeneca has a presence in all corners of the world and the company operates in over 100 countries. It has manufacturing and commercial operations distributed across major markets including North America, Europe, Asia, and emerging economies.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage